Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
04 11 2020
Historique:
received: 04 10 2019
accepted: 12 10 2020
entrez: 5 11 2020
pubmed: 6 11 2020
medline: 15 12 2020
Statut: epublish

Résumé

Close proximity between cytotoxic T lymphocytes and tumour cells is required for effective immunotherapy. However, what controls the spatial distribution of T cells in the tumour microenvironment is not well understood. Here we couple digital pathology and transcriptome analysis on a large ovarian tumour cohort and develop a machine learning approach to molecularly classify and characterize tumour-immune phenotypes. Our study identifies two important hallmarks characterizing T cell excluded tumours: 1) loss of antigen presentation on tumour cells and 2) upregulation of TGFβ and activated stroma. Furthermore, we identify TGFβ as an important mediator of T cell exclusion. TGFβ reduces MHC-I expression in ovarian cancer cells in vitro. TGFβ also activates fibroblasts and induces extracellular matrix production as a potential physical barrier to hinder T cell infiltration. Our findings indicate that targeting TGFβ might be a promising strategy to overcome T cell exclusion and improve clinical benefits of cancer immunotherapy.

Identifiants

pubmed: 33149148
doi: 10.1038/s41467-020-19408-2
pii: 10.1038/s41467-020-19408-2
pmc: PMC7642433
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
Membrane Proteins 0
Transforming Growth Factor beta 0
Endopeptidases EC 3.4.-
Serine Endopeptidases EC 3.4.21.-
fibroblast activation protein alpha EC 3.4.21.-
Gelatinases EC 3.4.24.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5583

Références

Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Immunogenetics. 1990;31(4):245-52
pubmed: 1691737
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Nat Rev Urol. 2016 Jul;13(7):420-31
pubmed: 27324121
Cell. 2017 Aug 24;170(5):927-938.e20
pubmed: 28841418
J Immunol. 1988 Jun 15;140(12):4217-23
pubmed: 3131428
J Immunother Cancer. 2018 Jul 17;6(1):75
pubmed: 30012210
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
J Natl Cancer Inst. 2013 Aug 21;105(16):1172-87
pubmed: 23852952
J Cell Sci. 2003 May 15;116(Pt 10):1863-73
pubmed: 12692188
PLoS Comput Biol. 2013;9(8):e1003118
pubmed: 23950696
Clin Cancer Res. 2016 Feb 15;22(4):813-20
pubmed: 26880610
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
F1000Res. 2013 Dec 04;2:264
pubmed: 24701342
Cell Rep. 2020 Apr 14;31(2):107502
pubmed: 32294438
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Clin Cancer Res. 2014 Feb 1;20(3):764-75
pubmed: 24240112
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Nat Biotechnol. 2015 Nov;33(11):1152-8
pubmed: 26372948
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8151-E8158
pubmed: 27911817
Epigenetics. 2014 Nov;9(11):1461-72
pubmed: 25470663
Blood. 2011 Jul 14;118(2):330-8
pubmed: 21551236
Nat Genet. 2020 Jun;52(6):582-593
pubmed: 32483290
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Front Immunol. 2017 Dec 08;8:1617
pubmed: 29276510
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Lancet Oncol. 2015 Aug;16(8):928-36
pubmed: 26115797
J Biol Response Mod. 1990 Apr;9(2):113-26
pubmed: 2111373
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72
pubmed: 12011421
Int Immunol. 2016 Jul;28(7):339-48
pubmed: 27055470
Immunology. 1995 Oct;86(2):263-9
pubmed: 7490128
Nucleic Acids Res. 2013 Apr;41(7):e90
pubmed: 23476028
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
Cancer Discov. 2018 Dec;8(12):1518-1528
pubmed: 30442708
Genomics. 2011 Oct;98(4):288-95
pubmed: 21839163
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Bioinformatics. 2010 Apr 1;26(7):873-81
pubmed: 20147302
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cell. 2018 Jun 14;173(7):1755-1769.e22
pubmed: 29754820
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9944-8
pubmed: 8234339
Nat Commun. 2018 Sep 24;9(1):3868
pubmed: 30250229
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
J Immunother Cancer. 2017 Aug 15;5(1):68
pubmed: 28807024
J Immunother Cancer. 2018 Jun 4;6(1):47
pubmed: 29866156
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Genome Biol. 2014 Dec 03;15(12):503
pubmed: 25599564
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Cancers (Basel). 2019 May 14;11(5):
pubmed: 31091744
Clin Cancer Res. 2014 Apr 15;20(8):2080-91
pubmed: 24573554
J Biol Chem. 2015 Oct 30;290(44):26562-75
pubmed: 26381407
Methods Mol Biol. 2016;1418:283-334
pubmed: 27008021
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
J Clin Invest. 2013 Jan;123(1):517-25
pubmed: 23257362
Oncotarget. 2017 Dec 19;9(3):4120-4133
pubmed: 29423109
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308

Auteurs

Mélanie Desbois (M)

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.

Akshata R Udyavar (AR)

Department of Bioinformatics & Computational Biology, Genentech, Inc., South San Francisco, CA, USA.

Lisa Ryner (L)

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.

Cleopatra Kozlowski (C)

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.

Yinghui Guan (Y)

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.

Milena Dürrbaum (M)

Department of Bioinformatics & Computational Biology, Genentech, Inc., South San Francisco, CA, USA.

Shan Lu (S)

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.

Jean-Philippe Fortin (JP)

Department of Bioinformatics & Computational Biology, Genentech, Inc., South San Francisco, CA, USA.

Hartmut Koeppen (H)

Department of Research Pathology, Genentech, Inc., South San Francisco, CA, USA.

James Ziai (J)

Department of Research Pathology, Genentech, Inc., South San Francisco, CA, USA.

Ching-Wei Chang (CW)

Department of Biostatistics, Genentech, Inc., South San Francisco, CA, USA.

Shilpa Keerthivasan (S)

Department of Cancer Immunology, Genentech, Inc., South San Francisco, CA, USA.

Marie Plante (M)

Laval University Cancer Research Center, Hôtel-Dieu-de-Québec, Centre Hospitalier Universitaire (CHU) de Québec, 11 Côte du Palais, Québec, QC, G1R 2J6, Canada.

Richard Bourgon (R)

Department of Bioinformatics & Computational Biology, Genentech, Inc., South San Francisco, CA, USA.

Carlos Bais (C)

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.

Priti Hegde (P)

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.

Anneleen Daemen (A)

Department of Bioinformatics & Computational Biology, Genentech, Inc., South San Francisco, CA, USA.

Shannon Turley (S)

Department of Cancer Immunology, Genentech, Inc., South San Francisco, CA, USA.

Yulei Wang (Y)

Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA. wang.yulei@gene.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH